Updated on 8 August 2012
"We are excited, because this is the first study to investigate this class of microRNAs at the epigenetic level in prostate cancer," said Professor Susan Clark.
"The epigenome is a constantly changing set of biochemical modifications that directly impact upon gene expression - and in this case we showed extensive methylation of at least 10 microRNAs involved in prostate cancer, especially miRNA-205."
"Methylation has the effect of silencing a gene, and in this study hypermethylation of miRNA-205 was directly associated with poor prognosis for prostate cancer patients."
"This is a novel finding and we now aim to use this potential translational biomarker to screen a much larger clinical cohort, investigating how it might be used in the management of prostate cancer."